Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06483009 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy With Cryoablation in NSCLC

StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Phase: Phase 2 to Phase 4
    • Start date: Jul 2024 to Oct 2024
    • Primary and study completion dates: Jul 2027 to Oct 2027
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to investigate the efficacy and safety of immuno-chemotherapy in combination of cryoablation as the first-line treatment of advanced NSCLC
Trial Details
NCT Number NCT06483009
Lead Sponsor Shanghai Chest Hospital
Conditions
(from sponsor)		 Non-Small-Cell Lung Cancer
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov